Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $14.00 in the prior trading day, TG Therapeutics Inc (NASDAQ: TGTX) closed at $13.82, down -1.29%. In other words, the price has decreased by -$1.29 from its previous closing price. On the day, 3.06 million shares were traded. TGTX stock price reached its highest trading level at $14.13 during the session, while it also had its lowest trading level at $13.55.
Ratios:
Our goal is to gain a better understanding of TGTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.18 and its Current Ratio is at 5.92. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 02, 2023, Upgraded its rating to Neutral and sets its target price to $12 from $16 previously.
On May 20, 2022, BofA Securities started tracking the stock assigning a Underperform rating and target price of $5.BofA Securities initiated its Underperform rating on May 20, 2022, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 13 ’24 when Lonial Sagar sold 5,000 shares for $15.94 per share. The transaction valued at 79,675 led to the insider holds 108,878 shares of the business.
Charney Laurence N sold 22,000 shares of TGTX for $351,340 on Mar 12 ’24. The Director now owns 215,229 shares after completing the transaction at $15.97 per share. On Jan 05 ’24, another insider, Charney Laurence N, who serves as the Director of the company, sold 17,500 shares for $19.03 each. As a result, the insider received 333,025 and left with 237,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 2134098048 and an Enterprise Value of 1894527104. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 980.14, and their Forward P/E ratio for the next fiscal year is 31.01. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.13 while its Price-to-Book (P/B) ratio in mrq is 13.04. Its current Enterprise Value per Revenue stands at 8.108 whereas that against EBITDA is 90.891.
Stock Price History:
Over the past 52 weeks, TGTX has reached a high of $35.67, while it has fallen to a 52-week low of $6.46. The 50-Day Moving Average of the stock is -9.00%, while the 200-Day Moving Average is calculated to be -0.63%.
Shares Statistics:
The stock has traded on average 3.57M shares per day over the past 3-months and 2493930 shares per day over the last 10 days, according to various share statistics. A total of 151.42M shares are outstanding, with a floating share count of 139.66M. Insiders hold about 9.56% of the company’s shares, while institutions hold 58.81% stake in the company. Shares short for TGTX as of 1711584000 were 34355023 with a Short Ratio of 9.63, compared to 1709164800 on 34841369. Therefore, it implies a Short% of Shares Outstanding of 34355023 and a Short% of Float of 27.27.
Earnings Estimates
The performance of TG Therapeutics Inc (TGTX) in the stock market is under the watchful eye of TG Therapeutics, Inc. analysts actively contributing to its current rating.The consensus estimate for the next quarter is $164.47, with high estimates of $9.14 and low estimates of $1.34.
Analysts are recommending an EPS of between $Consumer Cyclical and $Healthcare for the fiscal current year, implying an average EPS of $Consumer Defensive.
